{
    "clinical_study": {
        "@rank": "163086", 
        "acronym": "INTREPID", 
        "arm_group": [
            {
                "arm_group_label": "Medium continuous dose of stimulation.", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects in this arm will receive a medium continuous dose of stimulation that may have been effective in previous DBS patients."
            }, 
            {
                "arm_group_label": "Low intermittent dose of stimulation.", 
                "arm_group_type": "Sham Comparator", 
                "description": "Subjects in this arm will be receiving a lower intermittent dose of stimulation which is less likely to be effective."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and effectiveness of Boston Scientific's\n      Vercise Deep Brain Stimulation (DBS) system in the treatment of patients with with advanced,\n      levodopa-responsive bilateral Parkinson's disease (PD) which is not adequately controlled\n      with medication."
        }, 
        "brief_title": "Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease", 
        "completion_date": {
            "#text": "July 2021", 
            "@type": "Anticipated"
        }, 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "detailed_description": {
            "textblock": "The study is multi-center, prospective, double-blind, randomized (3:1) controlled trial."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Diagnosis of bilateral idiopathic PD (H&Y \u2265 2) with a duration of PD \u2265 5 years.\n\n          -  Persistent disabling Parkinson's disease symptoms or drug side effects (e.g.,\n             dyskinesias, motor fluctuations, or disabling \"off\" periods) despite optimal medical\n             therapy.\n\n          -  Able to understand the study requirements and the treatment procedures and provides\n             written informed consent before any study-specific tests or procedures are performed.\n\n        Key Exclusion Criteria:\n\n          -  Any intracranial abnormality or medical condition that would contraindicate DBS\n             surgery.\n\n          -  Have any significant psychiatric condition likely to compromise the subject's ability\n             to comply with requirements of the study protocol\n\n          -  Any other active implanted devices including neurostimulators and /or drug delivery\n             pumps\n\n          -  Any previous thalamotomy, pallidotomy or subjects who have undergone a DBS procedure.\n\n          -  Have any significant medical condition that is likely to interfere with study\n             procedures or likely to confound evaluation of study endpoints.\n\n          -  A female who is breastfeeding or of child-bearing potential with a positive urine\n             pregnancy test or not using adequate contraception."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "22 Years"
        }, 
        "enrollment": {
            "#text": "310", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01839396", 
            "org_study_id": "G120075", 
            "secondary_id": "CDM00049710"
        }, 
        "intervention": {
            "arm_group_label": [
                "Medium continuous dose of stimulation.", 
                "Low intermittent dose of stimulation."
            ], 
            "description": "The Vercise\u2122 DBS system will be implanted in subjects in both study arms.  Stimulation parameters will vary depending on the study arm assignment.  All subjects will receive therapeutic settings at the end of the blinded period.", 
            "intervention_name": "Deep Brain Stimulation", 
            "intervention_type": "Device", 
            "other_name": "Vercise\u2122 Deep Brain Stimulation (DBS) system."
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Intrepid, Vercise, PD, DBS, Boston Scientific", 
        "lastchanged_date": "May 8, 2014", 
        "link": {
            "description": "INTREPID study website", 
            "url": "http://www.intrepiddbs.com"
        }, 
        "location": {
            "contact": {
                "email": "BSNClinicalTrials@bsci.com", 
                "phone": "855-213-9890"
            }, 
            "facility": {
                "address": {
                    "city": "Valencia", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91355"
                }, 
                "name": "Boston Scientific Clinical Research Information Toll Free Number"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Implantable Neurostimulator for the Treatment of Parkinson's Disease", 
        "overall_contact": {
            "email": "alexander.chernyak@bsci.com", 
            "last_name": "Alexander M Chernyak, BS", 
            "phone": "661-949-4855"
        }, 
        "overall_contact_backup": {
            "email": "Diane.Bowers@bsci.com", 
            "last_name": "Diane Bowers", 
            "phone": "661-949-4175"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Minnesota, Neurology Department", 
                "last_name": "Jerrold Vitek, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Universiry of California, San Francisco, Surgical Movement Disorders Clinic", 
                "last_name": "Philip Starr, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Difference in the mean change from baseline to 12 weeks post-randomization between the active and control groups in the ON time as measured by Parkinson's diary.", 
            "measure": "Improvement in ON time as measured by Parkinson's disease diary", 
            "safety_issue": "No", 
            "time_frame": "From baseline to 12 weeks post-randomization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01839396"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The UPDRS scale and quality of life assessments will be evaluated from baseline to 12 weeks post randomization.", 
            "measure": "Secondary Endpoints", 
            "safety_issue": "No", 
            "time_frame": "From baseline to 12 weeks post-randomization"
        }, 
        "source": "Boston Scientific Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boston Scientific Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}